The OncoMasTR qPCR test measures the expression of 3 prognostic genes (+ 3 reference genes) and estimates the probability of distant recurrence for breast cancer patients, thereby aiding clinicians in determining the best treatment options for their patients and avoiding the costs and severe side-effects from unwarranted chemotherapy, ultimately improving the quality of life of the patient. OncoMark continues to apply this methodology to identify novel signatures for prognosis and prediction in many other cancers including Prostate, Melanoma, Colorectal, Bladder, Multiple Myeloma and Lung cancers.
Bladder Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, Multiple Myeloma, Prostate Cancer
ER (Estrogen receptor), HER-2 (Human epidermal growth factor receptor 2)
Confirmatory trial(s)